Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists. :: SCD d'Orléans

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists.

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists.

Enregistré dans:

Détails bibliographiques
Format:	Article de revue numérique
Langue:	Indéterminée
Publié:	Journal of Visualized Experiments (JoVE) 2023.
Accès en ligne:	Accès Université d'Orléans
Note:	JOVE Education
Variante du titre:	Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Documents similaires

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids.
Publié: (2023)

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors.
Publié: (2023)

Peptic Ulcer Disease
Publié: (2023)

Peptic Ulcer Disease
Publié: (2021)

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents.
Publié: (2023)

Peptic Ulcer Disease IV: Management.
Publié: (2024)

Peptic Ulcer Disease I: Introduction.
Publié: (2024)

Peptic Ulcer Disease II: Pathophysiology.
Publié: (2024)

Drug-Receptor Interaction: Antagonist.
Publié: (2023)

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents.
Publié: (2023)

Pathophysiology of Peptic Ulcer Disease: Injurious Factors.
Publié: (2023)

Antiasthma Drugs: Muscarinic Receptor Antagonists.
Publié: (2023)

Histamine H4 receptor. A Novel Drug Target For Immunoregulation and Inflammation
par: Stark, Holger
Publié: (2021)

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors.
Publié: (2023)

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies.
Publié: (2024)

Peptic Ulcer Disease V: Surgical Management and Nursing Care.
Publié: (2024)

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists.
Publié: (2023)

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy.
Publié: (2023)

Histamine in the Brain
par: Maria Beatrice Passani, et autres
Publié: (2021)

Antiepileptic Drugs: Glutamate Antagonists.
Publié: (2023)

Adrenergic Antagonists: Chemistry and Classification of nb-Receptor Blockers.
Publié: (2023)

Adrenergic Antagonists: <U+0251> and nb-Receptor Blockers.
Publié: (2023)

Adrenergic Antagonists: Pharmacological Actions of nb-Receptor Blockers.
Publié: (2023)

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists.
Publié: (2023)

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists.
Publié: (2023)

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists.
Publié: (2023)

Adrenergic Antagonists: Chemistry and Classification of <U+0251>-Receptor Blockers.
Publié: (2023)

Adrenergic Antagonists: Pharmacological Actions of <U+0251>-Receptor Blockers.
Publié: (2023)

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists.
Publié: (2023)

Insomnia and beyond - Exploring the therapeutic potential of orexin receptor antagonists
par: Michel Alexander Steiner, et autres
Publié: (2021)

Drugs for Treatment of Ulcerative Colitis in IBD.
Publié: (2023)

Drug-Receptor Bonds.
Publié: (2023)

Drug-Receptor Interactions.
Publié: (2023)

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists.
Publié: (2023)

Crohn's Disease and Ulcerative Colitis
Publié: (2026)

Roles of Transporters and Receptors in Drug Delivery to the Brain in Health and Disease
Publié: (2025)

Enzymes Regulating the Homeostasis of Agonists and Antagonists of the N-Methyl D-Aspartate Receptors
Publié: (2021)

Drug-Receptor Interaction: Agonist.
Publié: (2023)

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants.
Publié: (2023)

Inflammatory Bowel Disease I: Ulcerative Colitis.
Publié: (2024)

© 2021-2023 • Université d'Orléans, Service Commun de Documentation, 6 rue de Tours, 45072 Orléans cedex 2
+33(0) 2 38 41 71 84 • https://scd.univ-orleans.fr • Mentions légales